Pharmacist Moms Group^™

Studying antibody–drug conjugates (ADCs) in patients ineligible for immunotherapy addresses a critical unmet need in PD-L1–negative metastatic TNBC, where targeted treatment options are limited.

If sacituzumab govitecan (SG) is approved for first-line metastatic TNBC, it could meaningfully shift clinical practice by providing an effective option for patients ineligible for immunotherapy or with PD-L1–negative disease.

Explore the complexities of hemophilia, its severity spectrum, and the emotional impact on patients and families in this insightful discussion.

Explore the latest FDA-approved therapies for non-small cell lung cancer, focusing on EGFR mutations and treatment strategies in oncology.

In the final segment, the panelists bring together the major insights from across the series, highlighting the most clinically meaningful data from monarchE, NATALEE, and VIKTORIA-1 and what these findings mean for the evolving role of CDK4/6 inhibitors in both early-stage and metastatic HR+ breast cancer.

Healthcare professionals discuss the risks of tardive dyskinesia in patients on dopamine receptor antagonists and emphasize the importance of education and monitoring.

Explore key updates in hemophilia management, focusing on patient support, bleeding management, and the pharmacist's vital role in treatment.

Experts discuss practical strategies for early recognition and coordinated care of tardive dyskinesia to enhance patient outcomes and quality of life.

Navigating FDA-Approved EGFR-Targeted Therapies in NSCLC